Table 2.

Demographic and clinical data from 57 kidney recipients (Tx group), 40 uremic patients (uremic controls), and 14 healthy controls, at baseline before transplantation

Tx GroupUremic ControlsHealthy Controls
n574014
Age, yr39 ± 13b47 ± 1139 ± 11
Gender, male/female38/1927/139/5
ESRD duration, mo24c (0 to 134)45 (1 to 168)-
BMI, kg/m224 ± 424 ± 424 ± 3
Waist-hip ratio0.92 ± 0.090.91 ± 0.080.81 ± 0.08a
Ever smoking, n (%)27 (47)26 (65)9 (64)
Diagnoses, n (%)
    glomerulonephritis28 (49)13 (33)-
    hypertensive kidney disease5 (9)11 (28)-
    vasculitis1 (2)1 (3)-
    PKD3 (5)    7 (18)-
    other/unknown20 (35)    8 (20)-
    apoplexi3 (5)3 (8)-
    former Tx11 (19)10 (25)-
Dialysis status, n (%)
    HD28 (49)28 (70)-
    CAPD19 (33)    9 (27)-
    predialysis10 (18)3 (8)-
    first-degree relatives with DM2 (4)    4 (10)2 (14)
Fasting p-glucose, mmol/L5.1 ± 0.55.1 ± 0.55.0 ± 0.3
p-glucose at 2 h, mmol/L7.4 ± 17.5 ± 25.4 ± 1a
HbA1c, %5.2 ± 0.45.2 ± 0.45.2 ± 0.2
ISI6.8 ± 4.07.9 ± 5.114.7 ± 7.0a
ISecr36.9 ± 18.531.4 ± 17.327 ± 14
SBP, mmHg142 ± 21141 ± 24118 ± 10a
DBP, mmHg85 ± 1383 ± 1473 ± 8a
Pulse69 ± 1172 ± 1161 ± 10a
  • Data are presented as mean ± SD or median (range), unless otherwise noted. Wilcoxon rank sum test or two-sample t test was used where appropriate to test. HD, hemodialysis; CAPD, continuous ambulatory peritoneal dialysis; Tx, transplantation; PKD, polycystic kidney disease; DM, diabetes mellitus; SBP, systolic blood pressure; DBP, diastolic blood pressure.

  • a Uremic patients versus healthy controls P < 0.0005.

  • b Tx group versus uremic controls P < 0.05.

  • c Tx group versus uremic controls P < 0.005.